Email updates

Keep up to date with the latest news and content from BMC Public Health and BioMed Central.

Open Access Research article

Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963–1968

Tomás J Aragón1234*, Skylar Ulrich24, Susan Fernyak34 and George W Rutherford2

Author Affiliations

1 Center for Infectious Disease Preparedness, School of Public Health, University of California, Berkeley, USA

2 Department of Epidemiology and Biostatistics, University of California, San Francisco, USA

3 Department of Medicine, University of California, San Francisco, USA

4 San Francisco Department of Public Health, City and County of San Francisco, USA

For all author emails, please log on.

BMC Public Health 2003, 3:26  doi:10.1186/1471-2458-3-26

Published: 11 August 2003

Abstract

Background

The United States (US) has re-instituted smallpox vaccinations to prepare for an intentional release of the smallpox virus into the civilian population. In an outbreak, people of all ages will be vaccinated. To prepare for the impact of large-scale ring and mass vaccinations, we conducted a systematic review of the complication and mortality risks of smallpox vaccination. We summarized these risks for post-vaccinial encephalitis, vaccinia necrosum (progressive vaccinia), eczema vaccinatum, generalized vaccinia, and accidental infection (inadvertant autoinoculation).

Methods

Using a MEDLINE search strategy, we identified 348 articles, of which seven studies met our inclusion criteria (the number of primary vaccinations and re-vaccinations were reported, sufficient data were provided to calculate complication or case-fatality risks, and comparable case definitions were used). For each complication, we estimated of the complication, death, and case-fatality risks.

Results

The life-threatening complications of post-vaccinial encephalitis and vaccinia necrosum were at least 3 and 1 per million primary vaccinations, respectively. Twenty-nine percent of vaccinees with post-vaccinial encephalitis died and 15% with vaccinia necrosum died. There were no deaths among vaccinees that developed eczema vaccinatum; however, 2.3% of non-vaccinated contacts with eczema vaccinatum died. Among re-vaccinees, the risk of post-vaccinial encephalitis was reduced 26-fold, the risk of generalized vaccinia was reduced 29-fold, and the risk of eczema vaccinatum was reduced 12-fold. However, the risk reductions of accidental infection and vaccinia necrosum were modest (3.8 and 1.5 fold respectively).